Great Lakes Advisors LLC Sells 50,406 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Great Lakes Advisors LLC decreased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 91,153 shares of the company's stock after selling 50,406 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.16% of Protagonist Therapeutics worth $2,090,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of Protagonist Therapeutics by 353.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,675 shares of the company's stock worth $153,000 after acquiring an additional 5,202 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Protagonist Therapeutics during the 4th quarter worth about $210,000. Teacher Retirement System of Texas grew its stake in shares of Protagonist Therapeutics by 6.1% in the 3rd quarter. Teacher Retirement System of Texas now owns 12,954 shares of the company's stock valued at $216,000 after buying an additional 740 shares in the last quarter. Obermeyer Wood Investment Counsel Lllp grew its stake in shares of Protagonist Therapeutics by 9.4% in the 3rd quarter. Obermeyer Wood Investment Counsel Lllp now owns 13,792 shares of the company's stock valued at $230,000 after buying an additional 1,180 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Protagonist Therapeutics by 11.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,338 shares of the company's stock worth $237,000 after buying an additional 1,093 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on PTGX shares. JMP Securities boosted their target price on shares of Protagonist Therapeutics from $42.00 to $45.00 and gave the stock a "market outperform" rating in a research report on Wednesday, May 8th. JPMorgan Chase & Co. boosted their price target on Protagonist Therapeutics from $34.00 to $37.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 28th. HC Wainwright reissued a "buy" rating and set a $38.00 price objective on shares of Protagonist Therapeutics in a report on Thursday, May 9th. Finally, StockNews.com raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Protagonist Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $38.00.

Insider Transactions at Protagonist Therapeutics

In other news, CFO Asif Ali sold 1,234 shares of the business's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $25.11, for a total transaction of $30,985.74. Following the transaction, the chief financial officer now owns 37,163 shares in the company, valued at approximately $933,162.93. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 30,000 shares of Protagonist Therapeutics stock in a transaction on Friday, March 1st. The shares were sold at an average price of $31.62, for a total transaction of $948,600.00. Following the sale, the chief executive officer now owns 574,590 shares in the company, valued at $18,168,535.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Asif Ali sold 1,234 shares of the stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the transaction, the chief financial officer now owns 37,163 shares of the company's stock, valued at approximately $933,162.93. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 83,457 shares of company stock worth $2,553,328. Insiders own 5.40% of the company's stock.

Protagonist Therapeutics Stock Up 1.4 %

PTGX stock traded up $0.45 during mid-day trading on Tuesday, reaching $31.71. 327,288 shares of the stock traded hands, compared to its average volume of 659,552. The firm has a market capitalization of $1.86 billion, a PE ratio of 13.00 and a beta of 2.09. The business has a 50-day moving average of $27.79 and a two-hundred day moving average of $24.94. Protagonist Therapeutics, Inc. has a 52 week low of $13.72 and a 52 week high of $33.34.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.39. The business had revenue of $60.00 million for the quarter, compared to the consensus estimate of $60.00 million. On average, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 1.67 EPS for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.